We are unwavering in our commitment to bring new options for people with chronic, debilitating neurological disorders.
Global Head of Neurology Development
Did you know
Neurological disorders are the leading cause of disability and second leading cause of death globally.1
people worldwide are estimated to live with multiple sclerosis (MS).2
Someone is diagnosed with or passes away from amyotrophic lateral sclerosis (ALS) every 90 minutes.3
Our commitment to neurology
We’re taking on the complex challenges of neurological diseases, advancing scientific understanding and developing treatments to address long-unmet needs.
Since 2012, we’ve been working to improve the lives of people with serious neuro-degenerative diseases. Our pipeline medicines address MS, ALS, Parkinson’s disease (PD), and chronic inflammatory demyelinating polyradiculoneuropathy.
Our neurology focus
Our neurology programs are built on a strong foundation of long-term partnerships with patients, physicians, advocates and researchers. Our goal is to slow or even halt neurodegeneration in MS, ALS, PD, and other neurological diseases.
Inspired by patients worldwide
What’s next in neurology?
For more than 18 years, we’ve worked relentlessly to deliver disease-modifying therapies for MS with distinct indications and mechanisms of action.4
We’re building on the success of two of our medicines, used to treat MS patients in more than 80 countries. Our clinical studies center on therapies’ “best-in-class” potential, based on technologies that target the underlying causes of these devastating diseases.
- Feigin V, Vos T, Nichols E, et al. (2019). The global burden of neurological disorders: translating evidence into policy. Lancet Neurol 19:255-265; DOI: 10.1016/S1474-4422(19)30411-9
- Multiple Sclerosis International Federation (2023). Atlas of MS. Accessed July 2023
- ALS Association (2021). Helping You Understand ALS. Accessed October 2022
- See Aubagio (teriflunomide) Summary of Product Characteristics, May 2021; Lemtrada (alemtuzumab) Summary of Product Characteristics, August 2021; and Cohen JA, et al. (2012) Lancet 380:1819-28; DOI: 10.1016/S0140-6736(12)61769-3
Page updated September 2023